Trial reportJournal of alternative and complementary medicine (New York, N.Y.)2015
Effect of the Probiotic Saccharomyces boulardii on Cholesterol and Lipoprotein Particles in Hypercholesterolemic Adults: A Single-Arm, Open-Label Pilot Study.
Trial report in Journal of alternative and complementary medicine (New York, N.Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Impact of probiotics and polyphenols on adults with heart failure: a systematic review and meta-analysis.European journal of medical research · 2025Pooled it
- Effect of Supplementation withNutrients · 2020Trial
- Probiotics: A Potential Strategy for Preventing and Managing Cardiovascular Disease.Nutrients · 2024Review
- The effect of synbiotic supplementation on plasma levels of advanced glycation end products and cardiovascular risk factors in hemodialysis patients: A double-blind clinical trial.Food science & nutrition · 2024Article
- Investigating the Efficacy ofInternational journal of molecular sciences · 2023Review
- Bile Salt Hydrolase-Competent Probiotics in the Management of IBD: Unlocking the "Bile Acid Code".Nutrients · 2022Review
- Effect of the Addition of Buckwheat Sprouts Modified with the Addition ofMolecules (Basel, Switzerland) · 2022Article
- Exploring biotechnological and functional characteristics of probiotic yeasts: A review.Biotechnology reports (Amsterdam, Netherlands) · 2022Review
- In Vitro Bile Salt Hydrolase (BSH) Activity Screening of Different Probiotic Microorganisms.Foods (Basel, Switzerland) · 2021Article
- Recognizing the Benefits of Pre-/Probiotics in Metabolic Syndrome and Type 2 Diabetes Mellitus Considering the Influence ofMicroorganisms · 2021Review
- Probiotic Characterization of Cholesterol-Lowering Lactobacillus fermentum MJM60397.Probiotics and antimicrobial proteins · 2020Article
- Effects of probiotics on the lipid profile: systematic review.Jornal vascular brasileiro · 2019Review
- New insights on atherosclerosis: A cross-talk between endocannabinoid systems with gut microbiota.Journal of cardiovascular and thoracic research · 2018Review
- The Interplay of Microbiome Dysbiosis and Cardiovascular Disease.Cardiology in reviewReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectivesElevated blood cholesterol levels are a major risk factor for coronary artery disease, the leading cause of death worldwide. Probiotics have been investigated as potential cholesterol-lowering therapies, but no previous studies have assessed the effect of the probiotic yeast Saccharomyces boulardii on cholesterol levels in human volunteers. The objective of this study was to examine the effect of S. boulardii on serum cholesterol and lipoprotein particles in hypercholesterolemic adults.
designThis study was a single-arm, open-label pilot study. SUBJECTS: Twelve hypercholesterolemic participants were recruited into the study; one dropped out.
interventionParticipants took 5.6×10(10) colony forming unit (CFU) encapsulated S. boulardii (Saccharomyces cerevisiae var. boulardii CNCM I-1079) twice daily for an 8-week period. OUTCOME MEASURES: Fasting concentrations of cholesterol (total cholesterol, low-density lipoprotein-cholesterol [LDL-C], high-density lipoprotein-cholesterol [HDL-C], and triglycerides), lipoprotein particles (very-low-density lipoprotein-particle [VLDL-P], remnant lipoprotein particle [RLP-P], total LDL-P, LDL III-P, LDL IV-P, total HDL-P, and HDL 2b-P), and additional cardiovascular biomarkers (apo B-100, lipoprotein [a], high-sensitivity C-reactive protein, homocysteine, fibrinogen, and insulin) were measured at baseline, after 4 weeks, and after 8 weeks.
resultsRemnant lipoprotein particles decreased by 15.5% (p=0.03) over the 8-week period. The remaining outcome measures were not significantly altered.
conclusionsIn this pilot study, 8 weeks of daily supplementation with S. boulardii lowered remnant lipoprotein, a predictive biomarker and potential therapeutic target in the treatment and prevention of coronary artery disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.